257 related articles for article (PubMed ID: 25915583)
1. Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease.
Ersek A; Xu K; Antonopoulos A; Butters TD; Santo AE; Vattakuzhi Y; Williams LM; Goudevenou K; Danks L; Freidin A; Spanoudakis E; Parry S; Papaioannou M; Hatjiharissi E; Chaidos A; Alonzi DS; Twigg G; Hu M; Dwek RA; Haslam SM; Roberts I; Dell A; Rahemtulla A; Horwood NJ; Karadimitris A
J Clin Invest; 2015 Jun; 125(6):2279-92. PubMed ID: 25915583
[TBL] [Abstract][Full Text] [Related]
2. RANKL cytokine enhances TNF-induced osteoclastogenesis independently of TNF receptor associated factor (TRAF) 6 by degrading TRAF3 in osteoclast precursors.
Yao Z; Lei W; Duan R; Li Y; Luo L; Boyce BF
J Biol Chem; 2017 Jun; 292(24):10169-10179. PubMed ID: 28438834
[TBL] [Abstract][Full Text] [Related]
3. Blocking glycosphingolipid production alters autophagy in osteoclasts and improves myeloma bone disease.
Leng H; Simon AK; Horwood NJ
Autophagy; 2024 Apr; 20(4):930-932. PubMed ID: 37771244
[TBL] [Abstract][Full Text] [Related]
4. Current topics in pharmacological research on bone metabolism: osteoclast differentiation regulated by glycosphingolipids.
Fukumoto S; Iwamoto T; Sakai E; Yuasa K; Fukumoto E; Yamada A; Hasegawa T; Nonaka K; Kato Y
J Pharmacol Sci; 2006 Mar; 100(3):195-200. PubMed ID: 16538029
[TBL] [Abstract][Full Text] [Related]
5. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo.
Farrugia AN; Atkins GJ; To LB; Pan B; Horvath N; Kostakis P; Findlay DM; Bardy P; Zannettino AC
Cancer Res; 2003 Sep; 63(17):5438-45. PubMed ID: 14500379
[TBL] [Abstract][Full Text] [Related]
6. Receptor activator of NF-κB ligand-dependent expression of caveolin-1 in osteoclast precursors, and high dependency of osteoclastogenesis on exogenous lipoprotein.
Hada N; Okayasu M; Ito J; Nakayachi M; Hayashida C; Kaneda T; Uchida N; Muramatsu T; Koike C; Masuhara M; Sato T; Hakeda Y
Bone; 2012 Jan; 50(1):226-36. PubMed ID: 22075210
[TBL] [Abstract][Full Text] [Related]
7. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
8. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
[TBL] [Abstract][Full Text] [Related]
9. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
10. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
[TBL] [Abstract][Full Text] [Related]
11. Osteocyte CIITA aggravates osteolytic bone lesions in myeloma.
Liu H; He J; Bagheri-Yarmand R; Li Z; Liu R; Wang Z; Bach DH; Huang YH; Lin P; Guise TA; Gagel RF; Yang J
Nat Commun; 2022 Jun; 13(1):3684. PubMed ID: 35760800
[TBL] [Abstract][Full Text] [Related]
12. A new osteoclastogenesis pathway induced by cancer cells targeting osteoclast precursor cells.
Wada A; Tsuchiya M; Ozaki-Honda Y; Kayamori K; Sakamoto K; Yamaguchi A; Ikeda T
Biochem Biophys Res Commun; 2019 Jan; 509(1):108-113. PubMed ID: 30578079
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades.
Ang E; Pavlos NJ; Rea SL; Qi M; Chai T; Walsh JP; Ratajczak T; Zheng MH; Xu J
J Cell Physiol; 2009 Aug; 220(2):450-9. PubMed ID: 19365810
[TBL] [Abstract][Full Text] [Related]
14. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
Yu X; Huang Y; Collin-Osdoby P; Osdoby P
J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
[TBL] [Abstract][Full Text] [Related]
15. Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients.
Colucci S; Brunetti G; Mori G; Oranger A; Centonze M; Mori C; Cantatore FP; Tamma R; Rizzi R; Liso V; Zallone A; Grano M
Leukemia; 2009 Nov; 23(11):2139-46. PubMed ID: 19587706
[TBL] [Abstract][Full Text] [Related]
16. Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2.
Yen CH; Hsu CM; Hsiao SY; Hsiao HH
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937821
[TBL] [Abstract][Full Text] [Related]
17. Protein phosphatase 2A as a new target for downregulating osteoclastogenesis and alleviating titanium particle-induced bone resorption.
Wang L; Guo X; Zhou W; Ding Y; Shi J; Wu X; Liu Y; Xu Y; Yang H; Geng D
Acta Biomater; 2018 Jun; 73():488-499. PubMed ID: 29656074
[TBL] [Abstract][Full Text] [Related]
18. Glycosphingolipid synthesis is essential for MDCK cell differentiation.
Pescio LG; Favale NO; Márquez MG; Sterin-Speziale NB
Biochim Biophys Acta; 2012 Jun; 1821(6):884-94. PubMed ID: 22387616
[TBL] [Abstract][Full Text] [Related]
19. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
20. Glycosphingolipid deficiency affects functional microdomain formation in Lewis lung carcinoma cells.
Inokuchi JI; Uemura S; Kabayama K; Igarashi Y
Glycoconj J; 2000; 17(3 -4):239-45. PubMed ID: 11201796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
